The Regulatory Science Series at University of Arizona presents Eslie Dennis, MD,Vice President and Head Global Medical Affairs Ventana Medical Systems, Inc., a member of Roche Group speaking on “Cancer, Pathology, and Precision Medicine: Virchow Revisited Through Grogan’s Lens” Available live at 3PM Eastern Apr 6 and archived at https://goo.gl/NGEBPt
By Dov Fox [Cross-posted from the Huffington Post Blog] It used to be that whether you got the child you wanted — or one you hadn’t planned on — was left to cosmic fate or the randomness of reproductive biology. Now, new powers of reproductive medicine and technology promise to deliver us from the vagaries…
By Timo Minssen We are pleased to announce a new publication in the International Review of Intellectual Property and Competition Law (IIC). Our paper analyzes new case law in European stem cell patenting and compares these developments with the US situation and International treaties. Further information and an abstract is available below: Authors: Ana Nordberg & Timo Minssen, University of Copenhagen, Centre…
By Daniele Carrieri, Angus Clarke, Anneke Lucassen, Susan Kelly Advances in genetic and genomic medicine are resulting in better diagnosis and treatment of some health conditions, and the question of whether former patients should be recontacted is therefore timely. Recontacting patients to inform them of new information or new testing, that could be relevant to their…
By I. Glenn Cohen My last post was a summary of the NAM’s Recommendations on Mitochondrial Replacement Therapy (MRT). Now here is my take on the report. But keep in mind the report was just released and all I could give it was a quick read, so these are really more like initial impressions:
By I. Glenn Cohen As readers know I’ve written on mitochondrial replacement therapy and its attendant ethical and regulatory issues. Today the National Academy of Medicine (formerly known as the IOM) released a terrific report today with its recommendations. I’ll have a second post with my reactions but here is a summary from the report…
The Future of Health Law and Policy: The Petrie-Flom Center’s 10th Anniversary Conference Celebration March 29, 2016 8:00 AM – 5:00 PM Wasserstein Hall, Milstein East ABC Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA The Petrie-Flom Center is celebrating its first decade and kicking off the next by looking at the future of health law…
By Mahsa Shabani Introducing data sharing practices into the genomic research has brought a number of concerns in research ethics and governance to the fore. For instance, research participants and the general public raised concerns about potential privacy issues in personal genomic data protection, as well as the scope of the secondary uses. In order to…
[Cross-posted from the Genomics Law Report blog] By Jennifer K. Wagner The Equal Employment Opportunity Commission (EEOC) is responsible for enforcing Title II of the Genetic Information Nondiscrimination Act (GINA), which prohibits employers from requesting genetic information (defined broadly) from their prospective, current, or former employees. GINA contains only six limited exceptions to this prohibition,…
By Holly Fernandez Lynch The public comment period on the NPRM to revise the Common Rule has just closed, and now we wait to see what happens (if anything), and when. One of the most controversial proposals in the NPRM would require at least broad consent for secondary research with biospecimens (i.e., research on specimens originally…
